Venlax75 mg

Venlax is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for the following conditions:

Established / FDA-approved uses

• Major Depressive Disorder (MDD) in adults.
• Generalized Anxiety Disorder (GAD) in adults.
• Social Anxiety Disorder (Social Phobia) in adults.
• Panic Disorder, with or without agoraphobia, in adults.

Off-label uses (evidence-based, not FDA-approved indications)

• Management of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause, when hormone therapy is contraindicated or not preferred.
• Prophylaxis of chronic migraine and certain neuropathic pain syndromes, used as an adjunct when first-line agents are inadequate.
• Attention-deficit/hyperactivity disorder (ADHD) as a second-line, off-label option in adults who have not responded to standard therapy.

The decision to use Venlax for any indication should be made by a qualified physician after weighing the potential benefits against risks.

Each tablet/capsule contains Venlafaxine Hydrochloride equivalent to the labelled strength of venlafaxine base (commonly available as 37.5 mg, 75 mg, and 150 mg extended-release or immediate-release strengths). Excipients vary by manufacturer and formulation (immediate-release tablet vs. extended-release capsule/tablet).

Venlax is a synthetic antidepressant belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class. It is structurally unrelated to tricyclic antidepressants, SSRIs, or other available antidepressant agents. Venlax and its major active metabolite, O-desmethylvenlafaxine (desvenlafaxine), are believed to act by potentiating neurotransmitter activity in the central nervous system.

Venlax is available in both immediate-release and extended-release (ER) oral formulations. The extended-release formulation allows once-daily dosing with a smoother plasma concentration profile and is generally preferred to reduce nausea and other dose-related side effects.

Antidepressant – Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Venlax is a member of this class.

Mechanism of Action

Venlafaxine Hydrochloride and its active metabolite inhibit the neuronal reuptake of serotonin and norepinephrine. At higher doses it also weakly inhibits dopamine reuptake. Unlike tricyclic antidepressants, Venlafaxine Hydrochloride has minimal affinity for muscarinic, histaminergic, or alpha-1 adrenergic receptors, which accounts for its more favorable side-effect profile with respect to anticholinergic and cardiovascular effects.

Pharmacokinetics

• Absorption: Well absorbed after oral administration; at least 92% of an oral dose is absorbed.
• Metabolism: Extensively metabolized in the liver, primarily via CYP2D6, to its active metabolite desvenlafaxine.
• Half-life: Approximately 5 hours for venlafaxine and 11 hours for desvenlafaxine.
• Excretion: Primarily renal, as parent drug and metabolites.

Extended-release capsules/tablets of Venlax should be swallowed whole with a full glass of water and should not be crushed, chewed, or divided, as this may alter the release characteristics. It should be taken at approximately the same time each day, with food, to reduce nausea. Immediate-release tablets are usually given in divided doses with food.

Venlax has the following well-established, clinically significant interactions:

• MAOIs: Concomitant use, or use within 14 days of stopping an MAOI, is contraindicated due to risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, mental status changes). MAOIs should not be started within 7 days of stopping Venlax.
• Serotonergic drugs (SSRIs, other SNRIs, triptans, tramadol, lithium, St. John's Wort): Increased risk of serotonin syndrome when combined with Venlax; monitor closely if co-administration is necessary.
• NSAIDs, aspirin, warfarin, and other anticoagulants/antiplatelets: Venlax may increase the risk of bleeding when combined with these agents due to effects on platelet function.
• CYP2D6 inhibitors (e.g., quinidine, paroxetine): May increase venlafaxine plasma levels; dose adjustment may be required.
• CNS depressants and alcohol: Additive sedation; caution advised regarding activities requiring mental alertness.

Common side effects of Venlax include:

• Nausea, dry mouth, constipation, decreased appetite
• Headache, dizziness, insomnia, somnolence, nervousness
• Sweating (diaphoresis)
• Sexual dysfunction (decreased libido, delayed orgasm, erectile dysfunction)
• Dose-dependent increase in blood pressure

Serious but less common effects include serotonin syndrome, activation of mania/hypomania, seizures, abnormal bleeding, hyponatremia (especially in elderly patients), and increased suicidal thinking/behavior in children, adolescents, and young adults (see Precautions and Warnings).

Pregnancy: Venlax should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Use of Venlax late in pregnancy has been associated with neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding in some cases; discuss the risks and benefits with a physician before use during pregnancy.

Lactation: Venlax and its active metabolite are excreted in human breast milk. Because of the potential for adverse effects in the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother, and only under medical supervision.

Boxed Warning: Venlax, like other antidepressants, increases the risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) with major depressive disorder and other psychiatric disorders. Patients of all ages should be monitored closely, especially during the first few months of therapy and following dose changes.

Other precautions

• Blood pressure: Venlax can cause sustained, dose-dependent increases in blood pressure. Blood pressure should be measured before starting treatment and monitored regularly, especially at higher doses.
• Serotonin syndrome: Risk increases when combined with other serotonergic agents (see Interactions).
• Discontinuation syndrome: Abrupt discontinuation can cause symptoms such as dizziness, nausea, headache, irritability, anxiety, and paresthesia, which tend to be more pronounced than with many other antidepressants; taper gradually under medical supervision.
• Hyponatremia: Cases of hyponatremia and SIADH have been reported, particularly in elderly patients and those on diuretics; monitor for symptoms such as headache, confusion, and weakness.
• Bleeding risk: Increased risk of abnormal bleeding, especially when used with NSAIDs, aspirin, or anticoagulants.
• Angle-closure glaucoma: Mydriasis associated with Venlax may trigger an angle-closure attack in patients with anatomically narrow angles.
• Use with caution in patients with a history of seizures, cardiac disease, or mania/bipolar disorder.

Overdose with Venlax, alone or with other substances, may cause tachycardia, seizures, altered level of consciousness, mydriasis, changes in cardiac conduction (QT prolongation), and, rarely, fatal outcomes. In case of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and should be carried out under close medical supervision; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Use with caution; may be more susceptible to hyponatremia and blood pressure changes. Consider slower titration.
• Renal impairment: Dose reduction required (see Dosage and Administration).
• Hepatic impairment: Dose reduction required (see Dosage and Administration).
• Pregnancy and lactation: See Pregnancy and Lactation section.
• Pediatric patients: See Pediatric Uses section.

Acute treatment with Venlax is generally continued for at least 4-6 weeks to assess response before considering a dose change. For major depressive disorder and anxiety disorders, maintenance treatment is typically continued for several months to reduce the risk of relapse, with the need for continued therapy reassessed periodically by the treating physician. Discontinuation should always be done gradually (see Dosage and Administration).

Venlafaxine Hydrochloride belongs to the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class of antidepressants.

Venlafaxine Hydrochloride and its active metabolite, desvenlafaxine, inhibit presynaptic reuptake of both serotonin and norepinephrine, increasing the availability of these neurotransmitters in the synaptic cleft. At higher doses, there is additional weak inhibition of dopamine reuptake. This dual/triple mechanism differentiates Venlafaxine Hydrochloride from selective serotonin reuptake inhibitors (SSRIs) and underlies its efficacy in depression and anxiety disorders.

C

The safety and efficacy of Venlax have not been established in patients younger than 18 years of age for major depressive disorder, and it is not approved for use in the pediatric population. Antidepressants, including Venlax, carry a boxed warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults. Venlax should not be used in pediatric patients unless specifically directed and closely monitored by a physician, and only when the potential benefit clearly outweighs the risk.